Jefferies Group Weighs in on Atara Biotherapeutics, Inc.’s FY2019 Earnings (ATRA)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Jefferies Group raised their FY2019 EPS estimates for Atara Biotherapeutics in a report issued on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biotechnology company will post earnings per share of ($5.23) for the year, up from their prior estimate of ($5.37). Jefferies Group has a “Buy” rating and a $30.00 price target on the stock. Jefferies Group also issued estimates for Atara Biotherapeutics’ FY2020 earnings at ($4.69) EPS and FY2021 earnings at ($3.49) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05).

A number of other brokerages also recently issued reports on ATRA. Goldman Sachs Group reissued a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday, September 11th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Finally, BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $24.40.

Shares of Atara Biotherapeutics (ATRA) opened at $14.80 on Friday. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Several hedge funds have recently bought and sold shares of ATRA. Eagle Asset Management Inc. increased its position in shares of Atara Biotherapeutics by 17.8% in the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after purchasing an additional 225,367 shares during the last quarter. Neuberger Berman Group LLC grew its position in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after acquiring an additional 147,061 shares during the last quarter. Morgan Stanley grew its position in Atara Biotherapeutics by 147.6% during the first quarter. Morgan Stanley now owns 175,058 shares of the biotechnology company’s stock valued at $3,597,000 after acquiring an additional 104,369 shares during the last quarter. Artal Group S.A. grew its position in Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Atara Biotherapeutics by 10.9% during the first quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock valued at $17,095,000 after acquiring an additional 81,634 shares during the last quarter. Institutional investors own 85.61% of the company’s stock.

In related news, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $15.30, for a total value of $91,800.00. Following the transaction, the executive vice president now directly owns 349,305 shares in the company, valued at $5,344,366.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,200 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $15.25, for a total transaction of $33,550.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares in the company, valued at $11,250,946.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,988 shares of company stock worth $670,920. 16.20% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Jefferies Group Weighs in on Atara Biotherapeutics, Inc.’s FY2019 Earnings (ATRA)” was reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://weekherald.com/2017/12/10/jefferies-group-weighs-in-on-atara-biotherapeutics-inc-s-fy2019-earnings-atra.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply